Recent advances in genome editing technologies have significantly enhanced making specific changes in the genomes of different types cells. Genetically engineered T cells, or the 'living drugs', is considered a new era in antitumor therapy. Current clinical trials using chimeric antigen receptors (CARs) T cells showed a promising result in patients with some intractable hematological malignancies. In this Review, some of the most recent advances in CAR T cell therapy are mentioned high lightening the use of genome editing in this field.
Hassan, R. (2017). Genome Editing and Chimeric Antigen Receptors T Cell Therapy. Suez Canal University Medical Journal, 20(2), 122-127. doi: 10.21608/scumj.2017.43560
MLA
Ranya Hassan. "Genome Editing and Chimeric Antigen Receptors T Cell Therapy", Suez Canal University Medical Journal, 20, 2, 2017, 122-127. doi: 10.21608/scumj.2017.43560
HARVARD
Hassan, R. (2017). 'Genome Editing and Chimeric Antigen Receptors T Cell Therapy', Suez Canal University Medical Journal, 20(2), pp. 122-127. doi: 10.21608/scumj.2017.43560
VANCOUVER
Hassan, R. Genome Editing and Chimeric Antigen Receptors T Cell Therapy. Suez Canal University Medical Journal, 2017; 20(2): 122-127. doi: 10.21608/scumj.2017.43560
)
View on SCiNiTO